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Abstract
Background: In the last few years, a new non-pharmacological treatment, termed apheresis, has been developed
to lessen the burden of ulcerative colitis (UC). Several methods can be used to establish treatment
recommendations, but over the last decade an informal collaboration group of guideline developers,
methodologists, and clinicians has developed a more sensible and transparent approach known as the Grading of
Recommendations, Assessment, Development and Evaluation (GRADE). GRADE has mainly been used in clinical
practice guidelines and systematic reviews. The aim of the present study is to describe the use of this approach in
the development of recommendations for a new health technology, and to analyse the strengths, weaknesses,
opportunities, and threats found when doing so.
Methods: A systematic review of the use of apheresis for UC treatment was performed in June 2004 and updated
in May 2008. Two related clinical questions were selected, the outcomes of interest defined, and the quality of the
evidence assessed. Finally, the overall quality of each question was taken into account to formulate
recommendations following the GRADE approach. To evaluate this experience, a SWOT (strengths, weaknesses,
opportunities and threats) analysis was performed to enable a comparison with our previous experience with the
SIGN (Scottish Intercollegiate Guidelines Network) method.
Results: Application of the GRADE approach allowed recommendations to be formulated and the method to be
clarified and made more explicit and transparent. Two weak recommendations were proposed to answer to the
formulated questions. Some challenges, such as the limited number of studies found for the new technology and
the difficulties encountered when searching for the results for the selected outcomes, none of which are specific
to GRADE, were identified. GRADE was considered to be a more time-consuming method, although it has the
advantage of taking into account patient values when defining and grading the relevant outcomes, thereby
avoiding any influence from literature precedents, which could be considered to be a strength of this method.
Conclusions: The GRADE approach could be appropriate for making the recommendation development process
for Health Technology Assessment (HTA) reports more explicit, especially with regard to new technologies.
Background
Ulcerative colitis and apheresis
Ulcerative colitis (UC) is a chronic disease of the colonic
mucosa that is commonly treated with corticosteroid
therapy to achieve clinical remission. Corticosteroids are
used empirically in patients with moderate-to-severe UC
despite the fact that relapse in patients who initially
responded to these drugs is common. In addition, ster-
oid therapy is associated with frequent side effects, espe-
cially when used for a long time [1]. In the last few
years, a new non-pharmacological treatment, termed
apheresis, has been reported to produce similar results
to those obtained with corticosteroids in terms of
disease remission [2-6].
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and platelet levels found in active UC resulting from the
activation behaviour and increased survival time of these
blood components [7]. Leukocytapheresis (LCAP) and
granulocytapheresis (GCAP)a r et h em o s tf r e q u e n t l y
used apheresis treatments [8], which usually involve five
sessions (one per week), although one or two sessions
per week can be used for a period of time ranging from
five to ten weeks [1,2,4,5,9,10]. However, the number of
sessions can vary depending on the severity of the disease
or the response to corticosteroid treatment, thus making
the comparison of different studies somewhat difficult
[11]. Hanai et al. reported that patients with severe active
UC who were corticosteroid-naïve responded readily to
granulocyte-monocyte apheresis (GMA), thereby avoid-
ing steroid therapy [3]. These observations indicate that
GMA might be a substitute for corticosteroid treatment
in these patients, thereby allowing them to avoid the pos-
sible side effects of these drugs.
It has been reported that approximately 20% of
p a t i e n t sw i t hU Ch a v eac h r o n i ca c t i v ed i s e a s et h a t
often requires several courses of systemic steroids to
achieve clinical remission. However, this treatment
regime is often followed by relapse of symptoms during
steroid tapering (continuous reduction of the dosage of
corticosteroids once the initial high dosage has pro-
duced significant clinical improvement) or soon after
their discontinuation.
Multiple studies have suggested that selective apher-
esis may be effective as a steroid-sparing treatment [12]
because the resulting reduction in the peripheral levels
of granulocytes and monocytes produced by GCAP
might mitigate inflammation and delay relapse during
steroid tapering in steroid-dependent patients [1].
Recommendation development
When assessing a health technology, many methodolo-
gies have been used to establish recommendations based
on existing systematic reviews or other study designs,
including SIGN (Scottish Intercollegiate Guidelines Net-
work) [13] and The Oxford Centre for Evidence-Based
Medicine [14]. The GRADE (Grading of Recommenda-
tions Assessment, Development and Evaluation)
approach has been developed by an informal collabora-
tion group of guideline developers, clinicians, and meth-
odologists with the aim of developing and disseminating
a sensible and transparent approach to grading quality
of evidence and strength of recommendations [15-17].
This approach is based on an assessment of other sys-
tems, including SIGN, and involves members from
numerous international organizations. It was created to
a s s e s st h eq u a l i t yo fe v i d e n c ea n de l a b o r a t er e c o m m e n -
dations in clinical guidelines [15,18-22], therefore the
application of this methodology would be of interest for
health technology assessment (HTA) reports.
Study objective
The objective of the present study was to use GRADE to
develop recommendations regarding the use of apheresis
devices for the treatment of UC, and to evaluate the
strengths, weaknesses, opportunities, and threats found
when using GRADE in this context in comparison with
those found previously using the SIGN method.
Methods
Definition of the clinical questions
We selected two of the possible questions concerning
the use of apheresis devices to treat UC using the PICO
model (Patients, Intervention; Comparison and Out-
comes) on the basis of two previously published docu-
ments [11,23]. These questions were as follows:
Question 1: Should apheresis devices be used to treat
non-steroid-dependent or non-steroid-refractory UC
patients to achieve clinical remission of the disease
rather than standard corticosteroid treatment?
Question 2: Should apheresis devices be used as an
adjunct treatment with corticosteroids to treat steroid-
dependent UC patients with the aim of sparing or
withdrawing corticosteroids rather than standard
corticosteroid treatment?
Definition and assessment of all Relevant Outcomes
Five researchers (NI-R, IG-I, RR-I, ML-A and ER-R)
defined the outcomes of interest for each question
based on prior work concerning the development of a
monitoring system for measuring the effectiveness and
safety of apheresis devices in UC patients [11]. The out-
comes defined for the first question were: clinical remis-
sion one month after treatment (defined as Mayo Index
≤ 2) [24]; endoscopic remission one month after treat-
ment (Endoscopic Mayo Subindex ≤ 1); and clinical
remission 12 months after treatment. The following
variables were defined to evaluate the safety of the treat-
ment: percentage of patients with mild adverse events
(those requiring continuing observation but no specific
therapy) and percentage of patients with moderate to
severe adverse events (with moderate events being
defined as those requiring transient therapeutic counter-
measures, but not interruption of therapy and severe
events those resulting in sequelae or increased risk of
death or requiring discontinuation of UC trial therapy).
The outcomes defined for the second question were as
follows: percentage of patients who do not require corti-
costeroids one month after the last apheresis session,
mean reduction of corticosteroids dose one month after
treatment, clinical remission one month after treatment
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remission one month after treatment (endoscopic subin-
dex ≤ 1 and no corticosteroids), improvement of quality
of life (as measured by the Inflammatory Bowel Disease
Questionnaire, or IBDQ, which is able to distinguish
between active UC disease and remission stage), colect-
omy rate during follow-up, percentage of patients with
long-term side-effects of both treatments, and clinical
remission maintained 12 months after treatment.
Each group member scored all defined outcomes from
1 to 9 (from least to most important). If major differ-
ences between individual scores were obtained, the rele-
vance of that particular outcome was discussed to reach
consensus. Critical outcomes were defined as those with
a final score of between 7 and 9, and important out-
comes as those with a final score of between 4 and
6 (See Table 1). Those outcomes scoring less than
4 points were not considered further.
Literature search and study selection
A previous systematic review [25] was used to assess the
use of apheresis devices in the treatment of UC. This
research was updated by searching the following data-
bases (up to May 2008): MEDLINE, Cochrane, EuroScan,
INAHTA, ISI, Current Controlled Trials, National
Guidelines Clearinghouse, New Zealand Guidelines
group, SIGN, Fisterra, Lilacs, GETECCU, and the
Cochrane-IBD (Inflammatory Bowel Disease) group.
Boolean operators were used to combine free text such
as ‘inflammatory bowel disease’, ‘ulcerative colitis’,
‘Crohn’sd i s e a s e ’, ‘apheresis’, ‘immunomodulation’, ‘leu-
kocytapheresis’, ‘granulocytapheresis’ and ‘lymphocyta-
pheresis’ with controlled vocabulary. The results of this
search were redefined using the Cochrane Collaboration’s
search filters to identify preferably randomized controlled
clinical trials. We included studies if: the effectiveness of
apheresis was assessed compared to conventional ther-
apy; the safety of apheresis was evaluated; or the cost-
effectiveness of the treatment was analysed. Case series
with less than ten patients and studies with no control
group were excluded [11].
Assessment of the outcomes
The overall quality of the evidence for each outcome
was assessed according to the considerations defined by
the GRADE approach: study design limitations that may
bias the estimates of the treatment effect; inconsistent
results due to unexplained heterogeneity; indirectness of
evidence because of indirect comparisons or indirect
population, intervention, comparator, or outcomes; and
imprecision of the included studies due to small sample
size, number of events, or wide 95% confidence inter-
vals. When possible, meta-analysis procedures using the
RevMan v.5 program were used to pool the data found
for the outcomes of interest. The information obtained
for each proposed question was summarised using the
GRADE profiler (GRADE Pro) v.3.2 program [26].
Agreeing on recommendations
After assessing the evidence found for each outcome,
the overall quality for each question was evaluated. The
balance between risks and benefits was discussed, and
the costs and patient values were taken into considera-
tion when available. Finally, the recommendations pro-
vided to the decision makers were graded and defined
by the group on the basis of all judgements made.
Table 1 Assessment of the importance of the defined outcomes
Outcomes of interest for the first question R1 R2 R3 R4 R5 Importance
1. Clinical remission one month after treatment 8 9 9 9 8 CRITICAL
2. Endoscopic remission one month after treatment 6 8 7 8 7 CRITICAL
3. Percentage of patients with mild adverse effects 8 6 7 6 5 IMPORTANT
4. Percentage of patients with moderate-to-severe adverse effects 9 8 9 8 8 CRITICAL
5. Clinical remission 12 months after treatment 7 6 8 6 8 IMPORTANT#
Outcomes of interest for the second question R1 R2 R3 R4 R5 Importance
1. Percentage of patients who don’t require corticosteroids one month after treatment 8 9 8 8 8 CRITICAL
2. Mean Reduction of Corticosteroids dose one month after treatment 9 6 7 6 6 IMPORTANT
3. Clinical remission one month after treatment (no corticosteroids) 8 8 7 8 8 CRITICAL
4. Endoscopic remission one month after treatment (no corticosteroids) 7 8 6 6 8 IMPORTANT
#
5. Improvement of Quality of life (Inflammatory Bowel Disease Questionnaire, or IBDQ) 7 8 8 6 9 CRITICAL
6. Colectomy rate during the follow-up 9 9 9 8 9 CRITICAL
7. Percentage of patients with long-term adverse effects 9 8 8 8 9 CRITICAL
8. Clinical remission 12 months after treatment 7 6 7 7 8 CRITICAL
*R1: Researcher n1; R2: Researcher n2; R3: Researcher n3; R4: Researcher n4; R5: Researcher n5.
# The group resolved by discussion that these outcomes should be considered as Important outcomes.
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bers of the GRADE working group (HJS), who super-
vised and resolved any doubts concerning the
methodological aspects of the process. JLC-N, a gastro-
enterologist and expert in inflammatory bowel disease
(IBD) who had previous experience with the assessed
treatment, reviewed the PICO questions and possible
outcomes for each defined question.
SWOT analysis to evaluate the use of the GRADE
approach for assessing new technologies
A SWOT (Strengths, Opportunities, Weaknesses and
Threats) analysis was performed to evaluate our use of
the GRADE approach to establish recommendations
concerning this new technology. Strengths were defined
as those attributes of the GRADE approach that were
helpful for achieving the objective, and weaknesses as
those attributes considered detrimental for this purpose.
Opportunities were defined as those external conditions
considered helpful for achieving the objective, and
threats as those external conditions which could be det-
rimental to the objective.
The group of researchers that developed this work
informally discussed the likely strengths, opportunities,
weaknesses, and threats found when using the GRADE
approach in this context. HJS did not participate in this
activity because of his role in the development of
GRADE. An evaluation was performed by each
researcher involved (NI-R, IG-I, RR-I, ML-A, ER-R), and
all the issues identified were summarized and discussed
to develop common themes. Each researcher scored all
of the items from 1 (least important) to 9 (most impor-
tant). Finally, the total and median scores for each issue
identified were calculated and used to order these issues
by importance.
Results
Results for the first question
‘Should apheresis devices be used to treat non-steroid-
dependent or non-steroid-refractory UC patients to
achieve clinical remission of the disease rather than
standard corticosteroid treatment?’
The consensus reached concerning the relative impor-
tance of the outcomes defined for this question is pre-
sented in Table 1. The controlled clinical studies reported
by Nishioka [5], Hanai [4], and Bresci [2] were included.
The patients studied by Sands [27] were not defined in
terms of the clinical scenarios considered in this study;
therefore this trial was not included in the analysis.
Table 2 summarizes the information found for each
outcome in a GRADE profile. When two or more stu-
dies were found for the same outcome, the data were
meta-analyzed (Figure 1A).
Some factors, such as the different definitions of clinical
remission in the studies selected, complicated the analysis
of the results. Although we used the Mayo Clinical Index
to define clinical and endoscopic remission, a large num-
ber of different indices and definitions can be used for the
same purpose [28], as was the case in some of these stu-
dies [1,2,5]. We found that the Rachmilewich Endoscopic
Index (EI) was most often used to define endoscopic
remission, although this outcome was not measured in the
included studies. Some of these studies did, however,
report the mean EI before and after treatment, therefore
we used this outcome as an indirect measure of endo-
scopic remission (Table 2). We judged this indirectness to
be serious enough to merit a further downgrade.
The findings for the first question can be summarised
as follows:
Balance between risk and benefits: there appears to be
no difference in efficacy between apheresis devices and
corticosteroids, both of which induce clinical remission
in both non-steroid-dependent and non-steroid-refrac-
tory patients one month after treatment, although the
effect of apheresis treatment is slower than that of corti-
costeroids in those patients that respond to them. The
incidence of adverse effects with LCAP seems to be sig-
nificantly lower than with high-dose corticosteroids,
although these effects are generally transient and, in
most cases, disappear during or shortly after the LCAP
sessions [29]. The adverse effects of a short course of
corticosteroids do not appear to be important.
Remarks: the balance between risks and benefits is
uncertain, although, in contrast to corticosteroids,
apheresis treatment appears to be associated with more
benefits than risks. The general quality of the evidence
found to answer the clinical question was very low (see
Table 2), although this treatment appears to have similar
remission rates to corticosteroid therapy. Apheresis
devices do not however seem to offer sufficient net ben-
efit in terms of lower costs and more rapid effect than
corticosteroids (in patients who respond to them) in this
clinical context. Acute course and tapering of predni-
sone treatment cost was estimated at 218.3 euros, and
the cost for Adacolumn® treatment at 6,500 euros [30].
In conclusion, in light of the limited adverse effects of
a two-month course of corticosteroids and their faster
induction of remission and notably lower price, apher-
esis devices are unlikely to be of greater benefit than
corticosteroid treatment in this context.
The panel therefore agreed on the following recom-
mendation:
‘For non-steroid-dependent and non-steroid-refrac-
tory UC patients, we recommend administration of
corticosteroids rather than apheresis devices (GCAP
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low quality of evidence.’
Results for the second question
’Should apheresis devices be used as an adjunct treat-
ment with corticosteroids to treat steroid-dependent UC
patients with the aim of sparing or withdrawing corti-
costeroids rather than standard corticosteroid
treatment?’
Table 1 shows the scores for the relative importance
for each defined outcome. The studies by Hanai [1] and
Sawada [10,29] were selected for this question. The ret-
rospective study of Jo et al. [31] was excluded because
the authors stated that compared groups were probably
different (apheresis treatment was more likely to have
been applied to patients resistant to or dependent on
prednisolone).
Table 3 shows the GRADE profile obtained for the
second question. A meta-analysis of the data was per-
formed for the following outcomes: clinical and endo-
scopic remission, and the reduction of the dose of
corticosteroids before and after treatment (Figure 1B).
The length of follow up, the different indices used to
define clinical and endoscopic remission and the lack of
results for some of the selected outcomes complicated
the assessment. Nevertheless, no differences in terms of
clinical remission when using different protocols have
been described in the literature [9,32].
The findings for the second question can therefore be
summarised as follows:
Balance between risks and benefits: Apheresis devices
appear to be associated with more benefits than risks. As
apheresis could mean that many patients with moderately
active UC are spared corticosteroid therapy [1], the appar-
ent risks of apheresis should be compared with the risks of
receiving continuous corticosteroid treatment.
Remarks: In this case, the balance between risks and
benefits is uncertain and only very low-quality evi-
dence was available to answer the question. Indeed, we
were only able to find a single study assessing the
cost of moderate-to severe UC in two scenarios: tradi-
tional treatment versus alternative treatment incorpor-
ating GCAP [30]. This study showed that the
incorporation of GCAP into the therapeutic manage-
ment of moderate-to-severe steroid-dependent UC
Figure 1 Meta-analysis performed for the outcomes related to each proposed clinical question.
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Page 7 of 11patients is cost-effective and results in savings related
to the reduction of adverse effects derived from corti-
costeroid use and a decreased number of surgical
interventions. With regard to the patients’ values and
preferences, we found that some UC patients refused
to be treated with corticosteroids [29,33]. Moreover, in
a recent study of Crohn’s disease patients’ preferences,
it was found that patients indicated a systematic pre-
ference for treatments that, amongst other issues,
avoided the need for steroids [34].
Thus, the panel agreed to make the following recom-
mendation:
‘We recommend that patients with steroid-depen-
dent UC should be treated with apheresis devices
(GCAP or LCAP) together with corticosteroids to
help them reduce or withdraw continuous corticos-
teroids intake (weak treatment recommendation,
very low quality of evidence)’
SWOT analysis to evaluate whether the GRADE approach
is appropriate for assessing new technologies
The SWOT analysis results regarding the suitability of
the GRADE approach for assessing new technologies are
presented in Table 4.
The most relevant strength found was that the elabora-
t i o na n dg r a d i n go ft h eq u a l i t yo fe v i d e n c ea n dr e c o m -
mendations starts at the very beginning of the process
with the definition and importance rating of the out-
comes for the proposed clinical question. The GRADE
approach also takes into account the patients’ values and
avoids the influence of any outcomes reported in the lit-
erature. In contrast, application of the GRADE approach
was considered to be more time-consuming than other
methods such as SIGN because information has to be
sought for all defined outcomes. Despite this, we consider
that using the GRADE approach in HTA, including new
technologies, could be beneficial due to its transparency
and systematic methodology.
Table 4 SWOT analysis results
Strengths Median
(total
score)
Weaknesses Median
(total
score)
S1: Elaboration and grading of the recommendations starts at the
beginning of the process when ranking the importance of the
outcomes
8
(39
points)
W1: Time-consuming method 8
(38
points)
S2: Patients’ values are considered to define and grade the outcomes,
thus avoiding the influence of literature results
8
(38
points)
W2: The strength of recommendations does not
only depend on the quality of the evidence found
6
(33
points)
S3: Patients’ opinions taken into account during the process 7
(37
points)
W3: Requires academic training to understand
how it works
7
(31
points)
S4: Explicit assessment of the quality of outcomes across studies 7
(35
points)
W4: Some elements continue to be developed 5
(29
points)
S5: Individual analysis of the outcomes, taking into account the ‘effect’
and applicability aspects during elaboration of the recommendations
7
(34
points)
S6: Collaboration from the beginning facilitates the acceptance of
results
7
(33
points)
Opportunities Median
(total
score)
Threats Median
(total
score)
O1: Possibility to use in HTA, including new technologies, due to its
transparency and systematic methodology
8
(38
points)
T1: Difficulties with new technologies: low
number of studies, heterogeneity, unsuitable
outcomes...
6
(34
points)
O2: Identifies outcomes to be considered in future research 7
(37
points)
T2: Complexity of the method can limit its use by
experts
7
(34
points)
O3: Developed software that helps the process 7
(37
points)
T3: Lack of institutional support 6
(25
points)
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The development of recommendations in healthcare
has always been problematic, and many different
methods have been used [13,14]. Over the last two
years, our group has been working on the introduc-
tion of the GRADE approach in the Spanish context
because this approach incorporates the advantages of
prior methods and continues to integrate new devel-
opments in health research methodology
[15,18-22,35,36]. The aim of the current study was to
apply this approach in a different context from the
development of typical clinical practice guidelines,
specifically the assessment of new and emerging
health technologies, and for this purpose we chose
the case of apheresis devices in UC treatment.
As a limitation of this study, we should note here that
we did not perform a controlled study comparing the
GRADE approach with another method for evaluating
the quality of evidence and strength of recommendations,
which would have been of interest in order to validate/
confirm our results in an objective manner. Nevertheless,
to learn from this study and draw conclusions about our
experience, we performed a SWOT analysis to analyze
the strengths, weaknesses, opportunities, and threats
found when using the GRADE approach in this context.
We should also point out that our results may be
influenced by our relatively limited experience with
using the GRADE approach. Indeed, our interpretation
may have been influenced by the impression of the par-
ticipants at several workshops we have run concerning
the correct use of the GRADE approach, who declared
it to be a more complicated method, particularly for
clinicians, and more time consuming than other systems
commonly used to elaborate clinical guidelines [37].
However, using the software and support material pro-
vided by GRADE may facilitate the production of evi-
dence profiles and enhance transparency when
formulating recommendations, as pointed out in our
SWOT analysis (Table 4, opportunity 3).
The inclusion of only one clinical expert could also be
a limitation of this study as having only ‘one point of
view’ could bias our work. This study was based on a
previous one undertaken in collaboration with four
experts in IBD, therefore the role of the clinical expert
in the current study was simply to resolve any doubts
that may have arisen related to this disease. For a future
controlled trial, it would be advisable to include more
clinical experts to cover possible different points of view.
Another limitation of this study, which is not specific
to GRADE, concerns the difficulties encountered in
finding data for some relevant outcomes that were not
measured or reported. This was the case for the out-
come ‘improvement of UC patients’ quality of life’,f o r
which the IBDQ questionnaire is frequently used. This
outcome was defined as critical for the second question,
although it was not measured in any of the included
studies. Similarly, despite recent reports showing that
GMA seems to be effective long-term [38,39], no direct
data were available for the outcome ‘clinical remission
after 12 months follow-up’. A similar situation was
found for the definition of clinical remission in steroid-
dependency, with some experts considering that this
should be accompanied by complete withdrawal of ster-
oids [33,38,40,41]. Our inability to locate these data
made the assessment of the evidence more challenging.
However, in the case of new technologies, the conclu-
sions obtained upon application of the GRADE
approach should help to ensure the correct definition of
the outcomes of interest, which should then be evalu-
ated in future research (Table 4, opportunity 2).
With regard to the strengths of this study, previous
work by GETECCU (The Spanish Group for the study
of Crohn’s disease and UC) group members facilitated
the definition of the outcomes of interest, which could
facilitate the acceptance of final recommendations by
clinicians (Table 4, strength 6). A qualitative study per-
formed after a training course concerning the GRADE
approach in Spain found that this approach was per-
ceived to be more sensitive to the issues faced by profes-
sionals in practice [37] because the relevant outcomes
are defined taking into account those outcomes consid-
ered to be important by both professionals and patients
rather than on the basis of literature findings (Table 4,
strength 2). As a consequence, the elaboration of recom-
mendations starts at the very onset of the process on
the basis of patients’ values and important outcomes
(Table 4, strength 1). We also attempted to take
patients’ values and preferences into account, which is a
key strength of this method (Table 4, strength 3).
With regard to the clinical questions selected, the lit-
erature studies found indicate that selective leukocyte
apheresis effectively removes activated granulocytes and
monocytes/macrophages from the peripheral blood of
UC patients while maintaining an excellent safety profile
[42]. Indeed, some studies have proposed the use of
apheresis devices as a first-line treatment for UC patients
rather than corticosteroid therapy [3], and others have
produced evidence regarding the efficacy of selective
apheresis as a steroid-sparing treatment [12], which
explains why these particular clinical questions were for-
mulated. Other questions related to the use of apheresis
devices in the treatment of UC could be proposed, such
as the possible use of apheresis treatment for paediatric
patients or patients with toxicity to corticosteroids.
The most challenging part of this study was the
assessment of the evidence found for each outcome,
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Page 9 of 11partly due to the context of the disease and the charac-
teristics of the new technology being assessed (Table 4,
threat 1). Whereas the SWOT analysis suggested that
the method was time consuming (Table 4, weakness 1)
and required some academic training (Table 4, weakness
3), both of which could be considered a limitation for
its use (Table 4, threat 2), evidence assessment is, in
general, complicated irrespective of whether GRADE or
other methods are used. It is therefore possible that
o t h e rm e t h o d sc o u l db em o r et i m ec o n s u m i n gi ft h e y
are expected to produce similarly transparent results.
Moreover, the GRADE approach offers the possibility of
making explicit judgements about the consistency, indir-
ectness, and precision of the results, which is considered
to be beneficial when applied to new and emerging
technologies (Table 4, opportunity 1 and strength 4).
We considered that the overall quality of the evidence
for each question should be based on the critical outcome
with the lowest quality of evidence. In our case, this qual-
ity was very low for both questions. As we have stated in
the SWOT analysis, the GRADE approach judges the rela-
tive importance of different outcomes and their trade-offs,
as well as the quality of evidence, explicitly rather than
implicitly [35], which in our opinion facilitates the discus-
sion and clarification of these judgements.
As we have mentioned before, although we consider
that the information obtained from the SWOT analysis
concerning the feasibility of using the GRADE approach
in this context is useful, we also think that a controlled
trial should be designed to study whether the recom-
mendations made differ when using different methodol-
ogies for this purpose. This would give more detailed
information regarding the utility of the GRADE
approach in this context.
Summary
Our study suggests that the GRADE approach could be
an appropriate means of making the recommendation-
formulation stage a more transparent part of the overall
process of producing HTA reports. Such reports are
especially relevant in the case of new technologies,
although we expect that most such assessments would
lead to weak recommendations due to the lack of infor-
mation that accompanies the introduction of new health
technologies. However, we also consider that this
approach would help to determine what future research
should take into account when new technologies are
assessed. Furthermore, more studies should be con-
ducted to develop the best approaches to making
recommendations about new health technologies.
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